Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
A phase 2 trial of Tislelizumab in advanced solid tumours, run by BeiGene, now recruiting.
Overview
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors is a phase 2 interventional study registered as NCT03736889 by BeiGene, with 200 participants planned, started 2018-09-19 and due to reach its primary completion in 2026-11. Interventions recorded: Tislelizumab (BGB-A317).
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Shares Tislelizumab, BeOne Medicines (formerly BeiGene), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SKB518 in Patients With Lung Cancer
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Shares Tislelizumab, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Shares Tislelizumab, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.